文献速递血管炎

儿童抗中性粒细胞胞质抗体相关血管炎的早期结局

Early Outcomes in Children With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
PubMed 文献 · Arthritis Rheumatol · 2017-06-09

该研究纳入105例儿童期起病的ANCA相关血管炎患者,评估12个月结局。42%在12个月达到缓解(PVAS为0且泼尼松<0.2 mg/kg/天),61%在12个月疾病不活动,63%在12个月存在至少1项PVDI损伤项。

要点

  • 12个月缓解率为42%,疾病不活动率为61%。
  • 诱导后4-6个月49%疾病不活动,92% PVAS改善≥50%。
  • 12个月时63%患者存在至少1项PVDI损伤项。

核心结论

  • 儿童ANCA相关血管炎中相当比例患者未达到缓解,但多数对治疗有反应。
  • 超过半数患者在疾病早期即出现多器官系统损伤。

研究设计与样本

  • 共纳入105例儿童期起病ANCA相关血管炎患者,诊断中位年龄13.8岁(四分位距10.9-15.8岁)。

主要发现

  • 42%患者在12个月达到缓解(PVAS为0且糖皮质激素剂量<0.2 mg/kg/天)。
  • 49%患者在诱导后(诊断后4-6个月)疾病不活动,61%患者在12个月疾病不活动。
  • 92%患者从诊断至诱导后PVAS评分改善至少50%。
  • 达到诱导后疾病不活动的51例患者中,12例(24%)发生轻微复发。
  • 12个月时PVDI损伤评分中位数为1(范围0-6),63%患者至少1项PVDI损伤项评为存在。

关键数值与推荐

  • 主要结局为12个月达到缓解,定义为PVAS为0且糖皮质激素剂量<0.2 mg/kg/天。
  • 次要结局包括疾病不活动(PVAS为0,不限激素剂量)、诱导后及12个月改善率、12个月损伤(改良PVDI,0=无损伤,1=存在1项损伤)及12个月复发率。

临床怎么用

  • 儿童ANCA相关血管炎治疗中应关注12个月缓解与疾病不活动评估。
  • 早期即需监测多器官系统损伤,PVDI可用于12个月损伤评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To characterize the early disease course in childhood-onset antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and the 12-month outcomes in children with AAV. METHODS: Eligible subjects were children entered into the Pediatric Vasculitis Initiative study who were diagnosed before their eighteenth birthday as having granulomatosis with polyangiitis (Wegener's), microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis (Churg-Strauss), or ANCA-positive pauci-immune glomerulonephritis. The primary outcome measure was achievement of disease remission (Pediatric Vasculitis Activity Score [PVAS] of 0) at 12 months with a corticosteroid dosage of <0.2 mg/kg/day. Secondary outcome measures included the rates of inactive disease (PVAS of 0, with any corticosteroid dosage) and rates of improvement at postinduction (4-6 months after diagnosis) and at 12 months, presence of damage at 12 months (measured by a modified Pediatric Vasculitis Damage Index [PVDI]; score 0 = no damage, score 1 = one damage item present), and relapse rates at 12 months. RESULTS: In total, 105 children with AAV were included in the study. The median age at diagnosis was 13.8 years (interquartile range 10.9-15.8 years). Among the study cohort, 42% of patients achieved remission at 12 months, 49% had inactive disease at postinduction (4-6 months), and 61% had inactive disease at 12 months. The majority of patients improved, even if they did not achieve inactive disease. An improvement in the PVAS score of at least 50% from time of diagnosis to postinduction was seen in 92% of patients. Minor relapses occurred in 12 (24%) of 51 patients after inactive disease had been achieved postinduction. The median PVDI damage score at 12 months was 1 (range 0-6), and 63% of patients had ≥1 PVDI damage item scored as present at 12 months. CONCLUSION: This is the largest study to date to assess disease outcomes in pediatric AAV. Although the study showed that a significant proportion of patients did not achieve remission, the majority of patients responded to treatment. Unfortunately, more than one-half of this patient cohort experienced damage to various organ systems early in their disease course.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Morishita KA, Moorthy LN, Lubieniecka JM, et al. Early Outcomes in Children With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol. 2017. PMID: 28371513. doi:10.1002/art.40112

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。